Isoelectric Focusing of Cerebrospinal Fluid Significance in Differential Diagnosis of Multiple Sclerosis

  • Sanja Grgić Univerzitetski klinički centar Republike Srpske; Medicinski fakultet Univerziteta u Banja Luci
  • Aleksandra Dominović Kovačević Univerzitetski klinički centar Republike Srpske. Medicinski fakultet Univerziteta u Banja Luci
  • Zoran Vukojević Univerzitetski klinički centar Republike Srpske. Medicinski fakultet Univerziteta u Banja Luci
  • Daliborka Tadić Univerzitetski klinički centar Republike Srpske, Medicinski fakultet Univerziteta u Banja Luci
  • Majda Nazalević Bursać Univerzitetski klinički centar Republike Srpske.
DOI: https://doi.org/10.5937/scriptamed56-56878

Sažetak


Background/Aim: Isoelectric focusing (IEF) of cerebrospinal fluid (CSF) is the gold standard for detecting intrathecal oligoclonal immunoglobulin G (IgG). Besides its diagnostic and predictive significance, the IEF method also has differential diagnostic impact in multiple sclerosis (MS). The goal of the research was to analyse the influence of IEF on the differential diagnosis of MS, as well as in neurology in general.

Methods: Research included 418 participants treated in the Neurology Clinic of the University Clinical Centre of the Republic of Srpska. Among them, 177 were suffering of MS. The control group, divided into major disease categories, consisted of 241 patients. The following were analysed for participants: demographic and clinical characteristics, IEF and cytobiochemical findings of CSF. Based on IEF findings, participants with oligoclonal bands (OB) were separated from those without OB. The findings of IEF in different disease categories and their differential diagnostic significance were analysed.

Results: In the examined cohort using the IEF method, intrathecal synthesis of oligoclonal IgG was evident only in inflammatory diseases, primarily multiple sclerosis and was absent in any non-inflammatory diseases. This indicated high sensitivity of the method for MS patients (96.6 %) and very high specificity for CNS inflammatory diseases (100 %).

Conclusion: IEF is a highly specific for CNS inflammatory diseases, indicating the differential diagnostic significance of oligoclonal IgG in MS, as well as in neurology in general.

Biografija autora

Sanja Grgić, Univerzitetski klinički centar Republike Srpske; Medicinski fakultet Univerziteta u Banja Luci

Klinika za neurologiju, Šef odjeljenja Centar za multiplu sklerozu

docent na Katedri za neurologiju, Medicinski fakultet Banja Luka

Reference

Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clin Med. 2020;20(4):380-3. doi: 10.7861/clinmed.2020-0292.

Gaetani L, Prosperini L, Mancini A et al. 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol. 2018;265(11):2684-7. doi: 10.1007/s00415-018-9048-8.

Cabrera MC. Oligoclonal bands: An immunological and clinical approach. Adv Clin Chem. 2022:109:129-63. doi: 10.1016/bs.acc.2022.03.004.

Arrambide G, Tintore M, Carmen E et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018; 141(4): 1075-1084. doi: 10.1093/brain/awy006.

Grgić S. [Importance of intrathecal oligoclonal immunoglobuline G in diagnosis and prognosis of multiple sclerosis] [dissertation]. Banja Luka: Faculty of Medicine, University of Banja Luka; 2013. Serbian.

Drulović J. [Analysis of oligoclonal immunoglobuline G in differential dijagnosis of neurological diseases] [dissertation]. Faculty of Medicine, University of Belgrade; 1994. Serbian.

Grgić S, Dominović-Kovačević A, Đajić V, Vukojević Z, Tadić D, Račić D, et al. Prognostic significance of intrathecal oligoclonal immunoglobulin G in multiple sclerosis. Scr Med 2020;51(3): 147-51. doi: 10.1007/s00415-018-9048-8.

Azzimonti M, Margoni M, Zanetta C, Genovese F, Martinelli V, Rocca MA, et al. Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis. J Neurol. 2024 Apr;271(4):1663-7. doi: 10.1007/s00415-023-12164-5.

Maglio G, D’Agostino M, Pio Caronte F. Multiple sclerosis: from the application of oligoclonal bands to novel potential biomarkers. Int J Mol Sci. 2024;25(10):5412. doi: 10.3390/ijms25105412.

Lourenco P, Shiran A, Saeedi J, Oger J, Schreiber A, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2013;19(5):577-84. doi: 10.1177/1352458512459684.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2.

Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014; 72(1):1-5. doi: 10.1159/000367614.

Oechtering J, Schaedelin S, Benkert P, Müller S, Achtnichts L, Vehoff J, et al; Swiss Multiple Sclerosis Cohort Study. Intrathecal immunoglobulin M Synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis. Ann Neurol. 2021 Sep;90(3):477-489. doi: 10.1002/ana.26137.

Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Nadj C, et al. The impact of Betaplus Program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicenter cross-sectional survey in the Western Balkan countries. Mult Scler Relat Disord. 2016;11:56-61. doi: 10.1016/j.msard.2016.12.002.

Jankowska A, Chwojnicki K, Szurowska E. The diagnosis of multiple sclerosis: what has changed in diagnostic criteria? Pol J Radiol. 2023;88:574-81. doi: 10.5114/pjr.2023.133677.

Engelborghs S, Niemantsverdriet E, Struyfs H. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017;8:111–26. doi: 10.1016/j.dadm.2017.04.007.

Dominques RB. The cerebrospinal fluid in multiple sclerosis: far beyond the bands. Einstein. 2017;15(1):100-4. doi: 10.1590/S1679-45082017RW3706.

Karrenbauer VD, Bedri SK, Hillert J, Manouchehrinia A. Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. Sci Rep. 2021;11(1):14987. doi: 10.1038/s41598-021-94423-x.

Katsarogiannis E, Landtblom AM, Kristoffersson A, Wikström J, Semnic R, Berntsson GS. Absence of oligoclonal bands in multiple sclerosis: a call for differential diagnosis. J Clin Med. 2023;12(14):4656. doi: 10.3390/jcm12144656.

Jin H, Lu Q, Gao F, Hao H. Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review. Ann Transl Med. 2023;11(7):282. doi: 10.21037/atm-21-3073.

Willis DM, Kreft LK, Dancey B. Oligoclonal bands. Pract Neurol. 2024;24(5):400-6. doi: 10.1136/pn-2023-003814.

Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK. the cerebrospinal fluid in multiple sclerosis. Front Immunol. 2019; 10:726. doi: 10.3389/fimmu.2019.00726.

Objavljeno
2025/04/30
Broj časopisa
Vol. 56 Br. 2 (2025): Mar-Apr
Rubrika
Originalni naučni članak
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).